Asset Details
Do you wish to reserve the book?
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
Do you wish to request the book?
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
2008
Overview
While the outcome for pediatric patients with lymphoproliferative disorders (LPD) or lymphoid malignancies, such as acute lymphoblastic leukemia (ALL), has improved dramatically, patients often suffer from therapeutic sequelae. Additionally, despite intensified treatment, the prognosis remains dismal for patients with refractory or relapsed disease. Thus, novel biologically targeted treatment approaches are needed. These targets can be identified by understanding how a loss of lymphocyte homeostasis can result in LPD or ALL. Herein, we review potential molecular and cellular therapeutic strategies that (i) target key signaling networks (e.g., PI3K/AKT/mTOR, JAK/STAT, Notch1, and SRC kinase family-containing pathways) which regulate lymphocyte growth, survival, and function; (ii) block the interaction of ALL cells with stromal cells or lymphoid growth factors secreted by the bone marrow microenvironment; or (iii) stimulate innate and adaptive immune responses.
Publisher
Humana Press Inc,Springer Nature B.V
Subject
Adjuvants, Immunologic - therapeutic use
/ Animals
/ Biomedical and Life Sciences
/ Enzyme Inhibitors - therapeutic use
/ Humans
/ Leukemia
/ Lymphoproliferative Disorders - metabolism
/ Lymphoproliferative Disorders - therapy
/ Oncology
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
/ Protein Kinases - metabolism
/ Receptor, Notch1 - metabolism
